Around two-thirds (67.1%) of patients with EGFR-mutant NSCLC have classical EGFR mutations (exon 21 L858R point mutation or exon 19 deletions [Ex19del]) [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.